Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, will present on
Thursday, February 13, 2014, at 2:15 p.m. ET during the 2014 Leerink
Global Healthcare Conference.
The session will be conducted as a fireside chat, or interview, format
and will be webcast live. The live webcast and replay can be accessed by
visiting the “Calendar of Events” section on the “Investors” page of
Enanta’s website at www.enanta.com.
A replay of the webcast will be available following the presentation and
will be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes – protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase – as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
Copyright Business Wire 2014